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Figure S1. TEM images of siRNA complexes with 5a (left), 5b (middle), and 5c (right). Figure S2 . VEGF expression using ELISA assays of A) siRNA concentration: 10 nM (n = 3); B) siRNA concentration: 1 nM (n = 3). Control (CTL): Untreated cell; negative control [Nat (-)]: natural siRNA without lipoplexes; positive control [Nat (+)]: natural siRNA treated with lipofectamine. The N/P ratios given in Table 1 .
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Experimental details
General Experiments and Analytical Conditions. All chemicals purchased from Sigma-Aldrich, Fluka, Lancaster, Proligo, or Glen Research and utilized without further purification. All reactions performed in flamedried glassware under argon. Flash column chromatography was performed using Merck silica gel 60 (230-400 mesh). High-resolution mass spectra (FAB) were obtained using a Jeol JMS700 high-resolution mass spectrometer at the Korea Basic Science Center, Daegu, Korea. MALDI-TOF mass spectra were recorded using a Kratos Shimadzu AXIMA-CFR MALDI-TOF mass spectrometer at the Bioneer Corporation. Purification of oligonucleotides was performed using an Agilent 1100 HPLC (VyDAC C18 column; 10 × 250 mm; 5 μm; pore size: 120 Å). The RT-PCR was performed using Corbert Research RG-6600 model. The siRNAs were synthesized using an Expedite 8909 synthesizer and primer oligonucleotides were purchased from Bionics Co., Ltd. (Korea).
1 H, 13 C, and 31 P NMR spectra were recorded using an FT-300 MHz Bruker Aspect 300 spectrometer. Chemical shifts of these spectra are reported in parts per million (ppm) downfield relative to the internal standard, tetramethylsilane (TMS). Coupling constants are reported in hertz (Hz). Spectral splitting patterns are designed as s, singlet; d, doublet; dd,double doublet; dt, distorted triplet; t, triplet; m, multiplet; and br, broad.
Experimental procedures of compounds 1, 2 and 3 are as in reference 7c. 150.5, 144.7, 140.6, 137.3, 135.4, 135.2, 129.8, 128.9, 128.2, 127.9, 127.7, 126.8, 125.3, 113.3, 101.5, 88.9, 85.9, 82.4, 73.4, 69.6, 63. 155.3, 154.8, 150.9, 144.3, 140.4, 135.4, 135.1, 130.6, 130.5, 130.4, 130.1, 129.8, 128.6, 128.5, 127.6, 115.8, 113.7, 103.2, 87.9, 85.4, 83.3, 77.8, 77.6, 77.4, 76.9, 73.8, 72.9, 72.7, 63.6, 55.6, 41.7, 41.6, 41.1, 33.0, 32.3, 32.1, 30.6, Supplementary Material (ESI) 154.9, 154.4, 150.4, 147.1, 140.9, 130.5, 130.3, 130.1, 128.0, 102.7, 86.5, 84.6, 84.2, 74.2, 72.7, 62.3, 62.0, 42.2, 41.6, 32.9, 32.2, 32.1, 31.8, 30.2, 30.1, 30.0, 29.8, 29.6, 29.5, 29.3, 27.5, 27 condition. Then corresponding polyamine (3 eq.) was added and the mixture was stirred for additional 12 h. After completion of the reaction, the solvent was evaporated under reduced pressure and extracted in CH 2 Cl 2 and washed with water, and brine. The organic layer was dried on Na 2 SO 4 and evaporated under reduced pressure.
5´-O-(
The crude compound was dissolved in methanol and Boc-anhydried (10 eq.) was added in the solution. Mixture was stirred for 2 h. After completion of the reaction, the solvent was evaporated under reduced pressure, extracted in 155.6, 155.2, 154.3, 154.0, 150.0, 139.2, 130.5, 130.3, 130.1, 128.0, 103.6, 86.5, 84.6, 84.2, 79.6, 74.2, 72.7, 62.3, 62.0, 42.2, 41.6, 35.8, 32.9, 32.2, 32.1, 31.8, 30.2, 30.1, 30.0, 29.8, 29.6, 29.5, 29.3, 28.8, 27.6, 27.4, 27.0, 23.1, 22.2, 20.7, 13.6 156.5, 156.1, 155.3, 155.1, 154.6, 151.2, 147.1, 140.4, 130.5, 130.3, 130.1, 128.0, 103.6, 86.5, 84.6, 84.2, 79.6, 74.2, 72.7, 62.3, 62.0, 42.2, 41.6, 35.8, 32.9, 32.2, 32.1, 31.8, 30.2, 30.1, 30.0, 29.8, 29.6, 29.5, 29.3, 28.8, 27.5, 27.3, 27.1, 23.0, 22.9, 14.5 155.2, 154.3, 154.0, 150.0, 139.2, 130.5, 130.3, 130.1, 128.0, 103.6, 86.5, 84.6, 84.2, 79.6, 74.2, 72.7, 62.3, 62.0, 42.2, 41.6, 35.8, 32.9, 32.2, 32.1, 31.8, 30.2, 30.1, 30.0, 29.8, 29.6, 29.5, 29.3, 27.5, 27.3, 27.1, 23.0, 22.2, 13.6 162.6, 156.6, 155.5, 155.3, 140.2, 130.5, 130.3, 130.1, 128.0, 103.6, 86.5, 84.6, 84.2, 79.6, 74.2, 72.7, 62.3, 62.0, 42.2, 41.1, 35.9, 32.8, 32.4, 32.0, 31.5, 30.2, 30.1, 30.0, 29.9, Supplementary Material (ESI) 29.6, 29.5, 29.1, 27.9, 27.8, 27.4, 23.0, 22.8, 14.7, 13.6; 6, 156.5, 155.3, 155.1, 151.2, 140.9, 130.5, 130.3, 130.1, 128.0, 103.6, 86.5, 84.6, 84.2, 74.2, 72.7, 62.3, 62.0, 42.2, 41.6, 35.8, 32.9, 32.2, 32.1, 31.8, 30.2, 30.1, 30.0, 29.8, 29.6, 29.5, 29.3, 27.5, 27.3, 27.1, 23.0, 22.9, 14.5 After cooling to room temperature, 10 volume of nuclease free water was added and the solution was vortexed and incubated at 4 o C before adding the siRNA. Lipoplexes were then prepared by mixing with corresponding siRNA quantities of each formulation with N/P ratio. Finally, the formulations were mixed and incubated for 30 min at room temperature before use.
WST-1 Assay. Lipids (with N/P ratio of 3, 7.5 and 12) were complexed with VEGF siRNA (certain concentration as for lipid) and added to the cells. Cells were incubated with complexes at 37 °C and 5 % CO 2 for 24 h. After incubation, media were removed, the cells washed with 100 mL of DPBS buffer (2 times) and then a 10 μL/well of cell proliferation reagent WST-1 to the cell already cultured in 100 mL/well (1:10 final dilution, Roche) was added to each well and incubated at 37 °C for 4 h. After incubation, absorbance were measured at a wavelength of 450 nm using a micro-plate reader (Asys) and converted to percentage of cell viability (relative to control cells).
